^
Association details:
| Biomarker: | ROS1 S1986Y + ROS1 S1986F |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers
Excerpt:
The patient's clinical response confirmed the potency of lorlatinib against S1986Y/F mutations.
DOI:
10.1158/1078-0432.CCR-16-0917
